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2Introduction
Welcome to AstraZeneca’s Corporate Social
Responsibility Report 2000. For the first time, we
have expanded our annual report on safety, health
and environmental performance to include some
information on other areas of corporate responsi-
bility. We intend to extend our reporting on social
issues progressively in line with the recommenda-
tions of the Global Reporting Initiative. This printed
report is a summary of the complete report which
is available on our website: www.astrazeneca.com
Scope
Following the creation of AstraZeneca in April
1999, we introduced a new SHE reporting system
that covers all of our facilities worldwide. We will
be using it to monitor our SHE performance in the
future. The data for 2000 is the baseline against
which our future performance will be compared. 
Unfortunately our 2000 data cannot be readily
compared with previous years because the com-
prehensive systems used by the heritage com-
panies Astra AB and Zeneca Group PLC were
different. 
This report covers all the facilities related to 
our healthcare businesses and Marlow Foods.
Businesses that have been divested from the
company during 2000 are excluded. 
Profile
AstraZeneca is one of the world's leading pharma-
ceutical companies which provides innovative,
effective products to fight disease in important
areas of medical need. Our company is research
and technology intensive, with extensive inter-
national development and marketing skills.
Our business is focused on seven major
therapeutic areas: cardiovascular, cen-
tral nervous system, gastrointestinal,
infection, oncology, pain control and
anaesthesia, and respiratory. 
We have worldwide operations with
corporate headquarters in London,
UK; research and development (R&D)
headquarters in Södertälje, Sweden; and 
a strong presence in the key US market.
AstraZeneca sells products in over 100 coun-
tries, manufactures in 19 countries and operates
six major research centres. We have over 50,000
employees worldwide.
Research & Development
Manufacturing
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3Message from
Tom McKillop, Chief Executive
AstraZeneca’s corporate SHE objectives for 2001/2002
Objective 1: We will aim to improve the safety, health and wellbeing of all our employees by introducing
behaviour-based programmes at all locations before July 1st 2002.
Objective 2: Our goal is to have no accidents or incidents and to minimise our environmental impact. During
2001 we will identify the key areas where improvement is a priority and the most useful indicators to measure 
our progress. Progress against these Key Performance Indicators will be published from 2002 onwards. 
Objective 3: We will publish information about our SHE performance using the internationally recognised
guidelines produced by the Global Reporting Initiative (GRI). 
Objective 4: Auditing is an essential part of continuous improvement. We began a Global SHE Management
Audit programme on April 1st and programmes for local SHE audits will be in place at all locations by the 
end of 2001.
Objective 5: We will aim to achieve a reduction in the growth of CO2 emissions from our facilities by 2005 
– this will be by an amount equivalent to 20% of 1998 emissions.
The impact on society of AstraZeneca’s activities is a
fundamental company consideration and we aim to
set, promote and maintain high standards of corporate
social responsibility worldwide. Earning and maintaining
society’s trust and confidence is essential to our con-
tinued success. 
We have key policies in place which support this
aim, and we are currently reviewing our activities
worldwide to ensure we can demonstrate that we are
acting appropriately and consistently in all markets.
This review includes developing a global strategic
approach to corporate social responsibility for the
company and areas for improvement. 
At the core of our corporate responsibility agenda 
is our commitment to good safety, health and environ-
mental performance, which is as strong as ever.
Backed by a clear policy and set of standards, we
have programmes in place that are beginning to 
deliver improvements. You can see the results here
and monitor our progress in the future.
As well as the SHE information, you will find details
in this summary and on our website of our approach 
to a range of social issues, together with examples of
how we are helping to make a difference in the com-
munities around us. 
A recent initiative of which I am especially proud 
is our $10 million capital investment in India to create 
a centre of excellence at our research facility in
Bangalore for the discovery and development of new
medicines of importance to the developing world. In
particular, work will focus on finding a new treatment
for tuberculosis, a disease that currently affects two
million people every year in India and 16 million people
worldwide. 
Corporate social responsibility is not an add-on
extra – it is an integral part of all that we do and I am
determined that we will continue to be a company that
is welcomed as a valued member of the global com-
munity.
4What is Sustainable Development?
Sustainable development has been defined as eco-
nomic activity that meets the needs of the present
generation without compromising the ability of future
generations to meet their own needs. Sustainability 
is frequently being viewed as the achievement of a
balance between the sometimes conflicting priorities 
of three components: economic, social and environ-
mental. 
Economic sustainability
We exist to provide good returns to our shareholders 
– in doing so we create employment, generate wealth
and pay taxes. The pharmaceuticals industry relies on
high levels of investment in research and development
to ensure its continuing economic sustainability.
Detailed economic information about AstraZeneca can
be found in our Annual Report & Form 20-F.
Environmental sustainability
The objective of environmental sustainability is to
reduce society’s impact on the planet to a minimum 
in order to ensure that future generations have the
natural resources they need to prosper. The issues
most relevant to AstraZeneca are:
• climate change (resulting from energy use)
• ozone depletion (resulting from the use of some
products)
• photochemical smog formation (resulting from
emissions of volatile organic compounds (VOCs))
• impact on water resources (resulting from the use 
of water in manufacturing and emissions of waste
water).
Our environmental programme addresses all these
issues and we expect to achieve continuous improve-
ment. However, in reality, this will be constrained by
technical and economic factors.
Social sustainability
The objective of social sustainability is to provide a
better quality of life for all members of society. In order
to make our contribution to this objective we need to
understand the changing expectations of society. 
Our social objectives can be more clearly identified by
considering all of our stakeholders – employees, cus-
tomers, shareholders and the wider community – and
the impact, both positive and negative, that our opera-
tions could have on them.
Significant social issues for the pharmaceutical industry
include, amongst others:
• employee health and safety;
• employee development and consultation; 
• access to medicines in the developing world; 
• public concern about animal testing;
• gene-based medicines. 
We are continuing to address these and other
issues, and we report on our progress in some of
these areas in this report.
Sustainable Development
in the
Pharmaceuticals Industry
5We have a number of key policies in
place to ensure that we act appropriately
and consistently worldwide. Agreed by
our Board of Directors, they apply to all
employees and activities, and compliance
with them is mandatory. Our Safety,
Health & Environmental (SHE) Policy is
one example. This policy is supported by
a SHE management system and eight
operational standards. The SHE manage-
ment system has now been implemented
at all our facilities and is audited regularly.
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SHE Management
System
Delivering our Policies
Progress
The System has been communicated to all parts of the
company and has been fully implemented. There is a
need for further improvement especially with the man-
agement of contractors, toll operators and suppliers. 
The majority of facilities implemented the reporting sys-
tem. Work is now in progress to improve data quality.
75% of facilities have reviewed energy consumption.
Larger facilities have produced improvement plans and
targets, which in some cases have already been imple-
mented. Many of our smaller facilities consist of leased
office accommodation but, we are nevertheless looking
for continuous improvements across all areas. 
The majority of facilities have either completed an initial
improvement plan or are well advanced in its develop-
ment.
2000 Objectives
Policy, Standards & Management
System
• Communicated, accepted and understood
across the business by mid 2000 
• Implemented by end 2000 
The Reporting System (including the
annual Management Review)
• Fully operational by mid 2000
Site Energy Efficiency
• All sites to evaluate the potential for improv-
ing energy efficiency by the end 2000
• Establish cost effective targets for improve-
ment at local and corporate level 
Accidents, Incidents & Ill Health 
• Development of plans to ensure progress
towards the goal of zero accidents, inci-
dents and ill health throughout the company 
Progress against our previous short-term
SHE Objectives for 2000
6Ensuring the safety, health and wellbeing of employees and contractors is one of AstraZeneca’s
core corporate social responsibilities and an absolute priority for the company. 
The AstraZeneca SHE management system [see page 5] represents an integrated approach 
to managing safety, health and environmental performance. 
We have now implemented a common measurement and reporting system for SHE Perform-
ance across the company and 2000 will be the year against which our future performance will
be compared.
Health & Safety Performance
Corporate
Objectives
2001/2002
AstraZeneca’s Safety Performance
Accidents with Injury
Caught in machinery 8%
Manual handling 21%
Vehicle-related 21%
Slips/trips/falls 29%
Others 21%
Total Accidents with Injury in 2000: 370
Fatalities
Regrettably, there were two fatal accidents involving
AstraZeneca employees during 2000. One member 
of staff was killed in a road accident, and the second
drowned while attending a conference.
In response to these unfortunate events we are re-
emphasising our defensive driver training programmes
and have issued specific health and safety guidance to
our employees who attend conferences.
Accidents
In addition to the fatalities, there were 368 accidents
that resulted in injury. The most common causes of
injuries were slips, trips and falls, closely followed by
vehicle and manual handling accidents. Details are
shown in the chart.
Key data
Accident frequency rate: 4.2/million hours
The growing US sales
force is accomplishing
their objective by
incorporating a safe
driving program into
the training for new
Pharmaceutical Sales
specialists and District
Sales Managers.
• Our goal is to have no accidents or incidents and to
minimise our environmental impact. During 2001 we will
identify the key areas where improvement is a priority 
and the most useful indicators to measure our progress.
Progress against these Key Performance Indicators will
be published from 2002 onwards.
7AstraZeneca’s Occupational
Health Performance
There were 310 cases of work-related ill health report-
ed during 2000. Upper-limb disorders (associated with
computer workstations, manufacturing and laboratory
activities) and work-related stress were the major
sources of illness. Details are shown in the chart.
Key data
Occupational illness frequency rate: 3.5/million hours
Occupational Illnesses
Skin disorders 7%
Musculo-skeletal disorders 46%
Travel illness 9%
Work-related stress illness 33%
Other occupational illness 5%
Total Instances of Occupational Illness in 2000: 310
AstraZeneca’s Approach 
to S H E
We believe that to improve our SHE performance we
have to modify individual behaviour. Therefore, we will
be promoting behavioural-based programmes at all 
our facilities. We aim to continue to improve the health,
safety and wellbeing of all our employees and the
sharing of examples of best practice.
The basis of our system is the recognition and man-
agement of risks to our business and our staff. We are
developing a system which will assist our managers to
identify priority areas and put in place appropriate sys-
tems to minimise the risks to our people, the environ-
ment and our business.
We have recognised that fire and natural hazards
such as earthquake present some of the biggest risks.
We are developing our processes to minimise the like-
lihood of these events having an adverse effect on our
people and operations.
Another priority is to reduce musculo-skeletal risks
in our laboratories, offices and manufacturing environ-
ments. We have set up cross-functional, international
project teams to identify the main causes, develop
common solutions and share best practice.
Our Senior Executive Team (SET) has recognised
that modern business can place great pressure on
individuals. They wish to promote programmes to help
our staff at all levels across the company develop a
healthy balance between life at work and life at home.
Many local programmes are already in place and have
been well received. The learning from these is being
shared across the Company and it is intended that
each facility should become involved in the pro-
gramme. To encourage further participation and inno-
vation, the most effective programme will receive a
special award from the Chief Executive. There will 
also be an additional award for the best project on a
specific theme, which for 2001 will be “Health and
Wellbeing”.
• We will aim to improve the safety, health
and wellbeing of all our employees by
introducing behaviour-based programmes
at all locations before July 1st 2002. 
Launched in June 2000, AstraZeneca do Brasil Ltda’s “Well-being” pro-
gramme is already producing results, with participants reporting personal
benefits which are positively influencing their performance in the workplace.
8AstraZeneca’s continued success depends
on our ability to attract and retain the best
people. 
We aim to promote a culture that values, recognises
and rewards outstanding performance and in which
employees share a commitment to AstraZeneca’s
objectives and to delivering their personal best. We
encourage and support people in developing their
potential to the full, against a background of equal
opportunity where individual success is based solely
on personal merit and performance. 
All managers are responsible for agreeing a person-
al development plan tailored to the individual skills and
aspirations of each member of their team. Everybody
is expected to play an active part in drafting their per-
sonal development plan and identifying training needs.
This includes a programme to develop global
leadership capabilities – implemented with the first 
200 senior managers – which will be extended to
more managers throughout 2001.
AstraZeneca’s reward policy closely links individual
reward with business performance at each level and
ensures alignment of the company’s, shareholders’
and employees’ interests. New, integrated reward and
benefit schemes are designed to meet varied and
changing employee needs around the world by intro-
ducing more choice and flexibility. 
In the UK in 2001, for example, the company has
introduced the ‘AZ Advantage’ flexible benefits scheme
which gives employees the opportunity to tailor their
reward package of cash and benefits to meet their
individual needs. 
We seek and listen to employee feedback. A global
opinion survey, involving 22,500 people across the
business was carried out in 2000 to benchmark opin-
ion in the company’s first year since merger. Positive
feedback was given about the considerable progress
the company has made relatively quickly to ensure that
employees were clear about AstraZeneca’s goals and
targets, and people felt empowered and supported in
their development. 
The survey also emphasised the importance and
need to improve the link between reward and recogni-
tion systems and performance. The challenge of man-
aging heavy work-load and maintaining an appropriate
home-work balance was also highlighted. These
issues are being addressed across the company, as
described above and in the Wellbeing section.
The full findings from the survey were communicat-
ed to employees worldwide – a selection of the find-
ings are on our web site – www.astrazeneca.com
Employee Development
and Consultation
AstraZeneca believes that healthy companies are
made up of healthy people. The Wellbeing programme
is designed to improve the physical and mental well-
being of employees. The aim of the programme, which
complements the existing occupational health and
safety programmes, is to help employees develop their
full potential and to be self confident and fulfilled. The
programme is designed to help employees manage
work-related stress better and avoid potentially damag-
ing effects.
Local Wellbeing programmes are well underway in
Brazil, Canada, France, the Philippines, Sweden, UK
and the US. These examples of best practice are
being shared within the company to encourage similar
initiatives in other locations. 
Wellbeing
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Laboratory Animals
Animal testing plays an essential role in the develop-
ment of new medicines and safety data derived from
animal testing is required by regulatory authorities
before new therapeutic agents can be tested on
humans.
In our research and development of medicines for
important areas of human healthcare, we use the most
modern scientific knowledge and techniques available.
These include both animal studies and non-animal
techniques. However, we aim to continue to reduce
the number of laboratory animals by using available
alternative methods such as computer modelling. We
take our responsibility towards the animals we study
very seriously and have a strict policy on the care and
use of laboratory animals.
R&D Investment in
Bangalore, India
AstraZeneca has announced plans for further invest-
ment in India to create a centre of excellence at its
facility in Bangalore for the discovery and development
of new medicines of importance to the developing
world. The research centre will focus principally on
finding a new treatment for tuberculosis. As a separate
entity, AstraZeneca maintains an interest in the AZ
Research Foundation, India, also located in Bangalore.
Both organisations demonstrate our commitment to
finding solutions to developing country diseases.
The Bangalore facility was originally set up in 1987
and the work of AZ R&D Bangalore is an integral part
of AZ’s R&D strategy. As part of a major investment
programme in India, a new laboratory will be built 
to house the AZ R&D facility, close to the existing  
AZ manufacturing site. Construction of the new facility,
which will be completed by the end of 2002, will pro-
vide direct benefit to the local economy. 
The choice of TB as the focus of research at
Bangalore accords with the World Health Organisa-
tion’s identification of 3 major targets for reducing the
impact of developing country diseases. TB, along with
malaria and HIV/AIDS, has been identified as a priority
area for new medicines. 
The research programme will involve collaborations
with academe and shared expertise with AstraZeneca’s
genomics and research centres in Boston, USA and
Alderley Park, UK.
The work will be reviewed by a Scientific Advisory
Board that includes 3 leading academics from Stanford
University, the Pasteur Institute and the WHO.
AstraZeneca has chosen TB as the
focus of research at Bangalore. TB 
has been identified as a priority area 
for new medicines by the World Health
Organisation for reducing the impact 
of developing country diseases
Bangalore, India
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Environmental Performance
Waste
Most of our active pharmaceutical products are manu-
factured using synthetic chemistry. The majority of the
waste we generate contains chemicals and solvents
used in these processes together with materials gener-
ated during formulation and packing operations. We
also treat many of our wastewater streams using on-
site biological treatment. The amounts of waste from
these processes are included in our figures together
with our general waste.
We classify our waste as either hazardous or non
hazardous according to the legislation in the country 
in which they are generated.
We believe that efficient use of resources and
recycling helps conserve natural resources, reduces
waste and saves money.
AstraZeneca’s Approach to S H E
Whilst a certain amount of waste is inevitable, waste
generation implies inefficient and costly use of raw
materials and avoidable waste disposal costs. There-
fore, efficient processes and re-use and recovery of
materials are priorities for us. Recycling of polyethylene
and polypropylene packaging waste from our manu-
facturing facilities has increased significantly. The mate-
rial is sent to companies outside AstraZeneca which
recycle a wide range of plastic raw materials. 
Where possible we avoid the use of hazardous
Hazardous Waste
Incineration with
energy recovery 47%
Incineration without
energy recovery 30%
Other treatment 20%
Recycled 2%
Landfill 1%
Total Hazardous Waste Produced in 2000: 31,000 tonnes
We recognise the value of benchmarking, both internal and external, as a means of evaluating 
our performance and increasing our contribution to sustainable development. We have compared
our emissions and consumption data with the values shown in the environmental reports of other
leading pharmaceutical sector companies. The results indicate that AstraZeneca’s impact is consis-
tently below the sector average. However, direct comparison is difficult because of the differences
in product portfolios and the processes used by the different companies. For details see our web
site www.astrazeneca.com
We are keen to develop this activity further and participate in leading benchmarking schemes,
for example the UK Business in the Environment Index, and to develop a common index for the
comparison of information
Use of resources
Benchmarking
Other Waste
Landfill 45%
Material recycling 27%
Incineration with
energy recovery 20%
Incineration without
energy recovery 4%
Other treatment 4%
Total Other Waste Produced in 2000: 30,000 tonnes
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Water
All our facilities discharge wastewater that is treated,
either on site or by the local sewage works. The dis-
charges are all subject to permits issued by local
authorities. Whilst we currently comply with all these
permits, it is our policy wherever possible to minimise
discharges to the environment.
Key data
Output Index
Parameter (tonnes) (mg/$ sales)
Phosphorus discharged 66 4 
Nitrogen discharged 62 4
Chemical Oxygen Demand 1,500 95
AstraZeneca’s Approach to S H E
As part of our process of continuous improvement, we
are upgrading effluent treatment at our manufacturing
facilities. For example, we are making a major invest-
ment to install on-site waste water treatment at our
Avlon facility in the UK. 
Air
Our operations result in a range of air emissions.
These include VOCs from our manufacturing opera-
tions, CO2 from the generation of the energy that we
use and from transport and CFCs, HCFCs and HFCs
arising from the propellants used in our products and
from our manufacturing facilities. 
Key data
Output Index
Parameter (tonnes) (mg/$ sales)
Total VOCs emitted to air 365 23
Total CFC 11 equivalents emitted 
to air during manufacturing 0.4 0.03
During 2000 we used about 14,000 tonnes of sol-
vents of which 1,100 tonnes were halogenated. We
have implemented processes for recovery, reuse and
recycling with the result that total emissions were
reduced to about 365 tonnes, of which about 30
tonnes were halogenated. 
We used about 8 tonnes of CFCs, 3 tonnes of
HCFCs and less than 0.5 tonnes of HFCs in 2000.
Only a small fraction of these were emitted as a result
of manufacturing processes. The ozone-depleting
potential of all substances emitted during manufactur-
ing was equivalent to 0.4 tonnes of CFC 11. 
AstraZeneca’s Approach to S H E
We are continuing to reduce VOC emissions from our
facilities. Replacement or upgrading of existing abate-
ment plants has significantly reduced emissions
already. We are gradually replacing the CFCs that are
still used with compounds which have minimal or sub-
stantially lower ozone-depleting potential.
The largest contribution to our total CFC emissions
is from propellant gases that are lost when patients
use our inhalers. We have been very active in the
development of alternatives to CFC-driven inhalers
(see chart) and this work is continuing.
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substances and disposals to landfill. Wherever pos-
sible, we treat waste so that it can be disposed of
safely and with minimal impact on the environment.
Key data
Output Recycled Index
Parameter (tonnes) (%) (g/$ sales)
Total hazarodus waste 31,000 2 2
Total other waste 30,000 27 2
Water Use
AstraZeneca used 5.3 million m3 of water in 2000 
(0.3 litres/$ sales). We recognise that water is a valu-
able natural resource which we can help to conserve
through efficient use and recycling.
AstraZeneca’s Approach to S H E
We are assessing the use of water throughout our
operations with priority being given to those regions
where water resources are scarce. Where possible,
we are introducing water-saving programmes, for
example in Australia our manufacturing facility has
reduced water consumption by 40,000 litres a day.
Discharges to 
the Environment
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Global warming is an increasingly important issue for governments and society. Carbon dioxide (CO2),
considered the principal global warming gas, is formed when fossil fuels are burnt to produce energy
for our processes and to heat and light our facilities. It is also generated by the vehicles and aircraft 
we use to transport our products and people. 
Key data
Parameter Output Index
Total energy use 1,950 (GWh) 0.12 (kWh/$ sales)
Total CO2 emissions 
from energy use 0.64 (M tonnes) 0.04 (kg/$ sales)
AstraZeneca’s Approach to S H E
We are constantly looking for ways to improve energy
efficiency and reduce CO2 emissions, to save the
business money and to lower our environmental
impact. Energy management programmes, group and
local targets, new technology (such as combined heat
and power plants) and increased awareness among
employees will help us meet our objective on CO2
emissions 
Energy by Source
Electricity 43%
Natural gas 39%
Other sources 7%
District heating 6%
Oil 5%
Total Energy Use in 2000: 1,950 Gigawatt hours (GWh)
CO2 Emissions from Energy Use
Purchased electricity 60%
Inhouse operations 40%
Total CO2 Emissions from Energy Use in 2000:
0.64 Million tonnes (M te)
Energy & Global Warming
In a complex global organisation such as AstraZeneca, 
it is difficult to produce precise data for transport-related
CO2 emissions. The following figures are our best
estimates.
Key data
Output Index
Parameter (M tonnes) (kg/$ sales)
Total CO2 emissions from transport 0.26 0.02
Business air travel in 2000 contributed about 0.1
million tonnes of CO2. Much of this was due to
increased travel associated with the company merger
and the figure should decrease in future. Business
travel by car amounted to 339 million kilometres, most
of this associated with sales and marketing. Product
distribution by road contributes least to our total CO2
emissions.
CO2 Emissions from Transport
Business air travel 38%
Business road travel 27%
Goods air transport 23%
Goods road transport 12%
Total CO2 Emissions from Transport in 2000:
0.26 Million tonnes (M te)
AstraZeneca’s Approach to S H E
By encouraging the use of telephone and video con-
ferencing throughout the business we are aiming to
reduce the total distance our employees travel every
year. We are reviewing our distribution network with 
a view to increasing the efficiency of the transport of
our products. 
Transport
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Corporate Objective 2001/2002: 
• We will aim to achieve a reduction in the growth of CO2 emissions from our facilities
by 2005 – this will be by an amount equivalent to 20% of 1998 emissions.
Whilst compliance with national legislation and our permits was generally very good, there were ten incidents of
non-compliance with operating permits in 2000. Seven of the ten incidents were associated with breaches of
emissions and discharge permits. Although regrettable, these incidents did not lead to any significant damage.
However, although AstraZeneca was not prosecuted, there is a possibility that one site may face legal action for
exceeding its consent to discharge methylene chloride.
The other three involved failures to obtain appropriate permits or submit information to regulatory authorities. 
The causes have been identified and action plans agreed with the regulatory authorities
Compliance
Pharmaceuticals in the Environment
The manufacture of pharmaceuticals is very highly
regulated and we aim to minimise the amounts of any
of our products being released to the environment in
effluent discharges from our facilities. However, we 
also recognise that small quantities of our products,
excreted by patients, may enter the environment. 
Improvements in analytical techniques have now
made it possible to detect very small concentrations of
some pharmaceuticals in the waste waters discharged
from sewage treatment plants. There have also been
reports of some widely used drugs being found in river
waters and sea waters.
AstraZeneca assesses the environmental fate and
effects of both its products and processes in line with
regulatory requirements for new drug applications.
Based on our current information, we do not believe
that there is any significant risk to either people or the
environment. In the vast majority of cases, the levels of
drug residues detected in the environment are many
times less than the minimum concentrations expected
to cause any significant environmental effects.
However, we are following developments in this area
very closely.  We are continuing to invest in advanced
waste treatment at our facilities and to collaborate with
regulatory agencies, academics and trade associations
throughout the world on this topic.
Other Issues
Our operations have a number of additional environmental impacts. For further details on these and the issues
already discussed, plus information on Land Use & Restoration and Products & Packaging, please visit our web-
site at www.astrazeneca.com. 
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On announcing the SHE awards for this year, Tom
McKillop said that he was very encouraged by the
dedication and inventiveness of people throughout 
the Business in delivering projects which provided 
the basis for very real improvements in our SHE per-
formance. “We have to look for new solutions to old
challenges if we are to meet our aspirational goal of
zero accidents and incidents” he said.
Over eighty projects had been entered. These 
had come from fifteen countries and represented all
parts of the business. Dr McKillop personally made 
the final selection from the short list presented by the
awards panel. This year the trophy was awarded to
AstraZeneca Canada for a series of related projects
that together improve the management and visibility 
of Safety, Health and Environmental Performance. The
projects included the development and implementation
of a local management system, management of con-
tractors, driving safety and a programme for personal
fitness. These were supported by a campaign to raise
the awareness of SHE issues across the Company. 
“I was especially pleased to see the importance that
the managers placed on improving an already good
SHE performance whilst delivering an outstanding busi-
ness performance” said Dr McKillop.
In addition to the trophy, three sites received “Highly
Commended Certificates”.
Brazil, for its programme of re-assessing the local
SHE issues and developing an integrated programme
for the National Marketing and Manufacturing
Operations.
UK Sales, for its project which focussed on pro-
moting safety at national sales conferences. Particular
emphasis had been put on the importance of safe
travel, personal security and sensible drinking.
Two contractors at Avlon Works UK were recog-
nised for the systems they had put in place to raise 
the importance of SHE among their own workforce
together with the provision of training and auditing
performance in the workplace.
Each of the winners also received a donation of
£2,000 for the charity of their choice. 
Further details of the CE awards are available on 
our web-site www.astrazeneca.com.
Chief Executive’s Awards
for Outstanding
Safety, Health and Environmental 
Performance
“I was especially pleased to see the importance that the managers placed
on improving an already good SHE performance whilst delivering an out-
standing business performance”
This year the trophy was awarded to AstraZeneca Canada for a series of related projects that together
improve the management and visibility of Safety, Health and Environmental Performance.
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Good SHE performance is essential for continued
business success. Considering the SHE-related
impact of all our activities is a fundamental part of our
operation. Our SHE policy, detailed below, reflects this
commitment, and sets out the baseline requirements
for our worldwide performance. 
Agreed by our Board of Directors, it applies to 
all employees and all activities, and compliance is
mandatory. To ensure compliance, the policy is
supported by a SHE management system and eight
operational standards (see page 5).
Our mission is to be first for innovation and value
in the provision of products and services to
improve human health and quality of life. Safety,
Health and Environmental (SHE) considerations 
are core to this and all our activities shall take
account of social, environmental and economic
factors, so as to:
Policy & Code of Conduct
• Meet or exceed legal requirements, regulations
and international agreements.
• Create a culture where SHE considerations are
integrated into all activities across the group.
• Conduct business as a responsible corporate
member of society committed to continual
improvements in all aspects of our SHE per-
formance.
• Provide a safe and healthy work environment 
for all our employees.
• Economise on the use of natural resources 
and work to minimise the impact on the environ-
ment.
• Aim to eliminate all injuries and incidents.
• Be amongst the industry leaders in SHE per-
formance.
• Provide information on our SHE performance
and communicate openly with all interested
parties.
We place the highest value on the reputation of the
AstraZeneca Group. We aim to earn the trust and con-
fidence of everyone we deal with by maintaining high
ethical standards at all times.
At the heart of our commitment is the AstraZeneca
Code of Conduct, published in June 2000, with which
all our employees are required to comply both in spirit
and letter. Integrity, honesty, diligence and care are
cornerstones of the Code.
The Code covers the following areas:
• Compliance
• Business practices
• Equal opportunities
• Personal harassment
• Political contributions
• Conflicts of interest
• Insider information
• Group property and resources
• Group policies, delegated authorities and reserved
powers.
The Code of Conduct and the Policy & Standards can be downloaded from our website at www.astrazeneca.com, 
or you can contact us directly for a printed copy. Please find contact details overleaf. 
SHE Policy
Code of Conduct
Contact information
Registered office
and corporate headquarters address:
AstraZeneca PLC
15 Stanhope Gate
London W1K 1LN
UK
Tel: +44 (0)20 7304 5000
Fax: +44 (0)20 7304 5183
R&D headquarters address:
AstraZeneca R&D Södertälje
S-151 85 Södertälje
Sweden
Tel: +46 (0)8 553 260 00
Fax: +46 (0)8 553 290 00
Investor relations contacts:
UK and Sweden: As above or e-mail:
investor-relations@astrazeneca.com
US:
Investor Relations
AstraZeneca LP
1800 Concord Pike
PO Box 15438
Wilmington
DE 19850-5438
US
Tel: +1 (302) 886 3000
Fax: +1 (302) 886 2972
www.astrazeneca.com
Thank you for taking the time to
read our report – we hope you have
found it informative. Further infor-
mation can be found on our website
at www.astrazeneca.com. Requests
for information and comments can
also be sent to Corporate Affairs
Department at Stanhope Gate,
London (see below) or via e-mail 
to CSR@astrazeneca.com
